Tirzepatide vs Semaglutide for Men: How to Choose Between Them

If you're a man looking at GLP-1 weight-loss medication, the first fork in the road is usually the molecule: semaglutide or tirzepatide. Most of what you'll read online compares providers and prices. This guide compares the drugs themselves — how they work, how they're dosed, what the one direct comparison trial showed, and the practical questions that tend to decide the choice.

The two molecules in one minute

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone that slows stomach emptying, increases fullness, and acts on appetite centers in the brain. For weight management it's sold as Wegovy; the diabetes version is Ozempic. An oral form also exists, which we cover in Oral Wegovy Pill vs Injectable.

Tirzepatide activates two receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. For weight management it's sold as Zepbound; the diabetes version is Mounjaro. The extra GIP action is the main hypothesis for why it tends to produce more weight loss, though the full mechanism is still being studied.

What the head-to-head trial found

For years the comparison relied on cross-trial guesswork. That changed with SURMOUNT-5, a 72-week randomized trial of 751 adults with obesity (or overweight plus a weight-related condition such as high blood pressure, sleep apnea or cardiovascular disease) who did not have diabetes. Participants took the maximum tolerated dose of either Zepbound or Wegovy.

• Average weight loss: 20.2% with tirzepatide vs 13.7% with semaglutide.
• Waist circumference: down 18.4 cm (7.2 in) with tirzepatide vs 13.0 cm (5.1 in) with semaglutide.

Two honest caveats. First, the trial was funded by Eli Lilly, which makes tirzepatide. Second, averages hide wide individual ranges: some men lose more on semaglutide than the average tirzepatide user, and some lose less on tirzepatide. The trial tells you which drug wins on average, not which one will work best for you.

Dosing and the titration experience

Both drugs start at a low dose that isn't meant to produce much weight loss — its job is to let your gut adapt. Semaglutide's weight-loss label climbs through five steps over 16 weeks before reaching the usual 2.4 mg maintenance dose. Tirzepatide starts at 2.5 mg for four weeks, then rises in 2.5 mg increments, each held for at least four weeks, with 5, 10 or 15 mg as maintenance options.

In practice, tirzepatide gives your clinician more maintenance "landing spots," which can help a man who tolerates 10 mg well but struggles at 15 mg. Semaglutide's label also allows a slower climb: if a dose isn't tolerated, the label suggests considering a four-week delay before escalating.

Missed doses are handled differently, too. Zepbound's label says a missed dose can be taken within four days; after that, skip it. Wegovy's label says to take a missed dose if the next one is more than two days away, and to restart escalation at a lower dose if two or more consecutive doses are missed. If you have had a gap in treatment, tell your prescriber before your next dose.

Side effects: more alike than different

The most common side effects for both drugs are gastrointestinal: nausea, diarrhea, vomiting, constipation, indigestion and abdominal discomfort. They cluster around dose increases and usually ease as your body adjusts. Both labels share the same serious warnings, including:

• A boxed warning about thyroid C-cell tumors seen in rodents. Neither drug should be used by men with a personal or family history of medullary thyroid carcinoma or MEN 2.
• Acute pancreatitis.
• Gallbladder problems, including gallstones and gallbladder inflammation.
• Dehydration-related kidney problems when vomiting or diarrhea is severe.

Head-to-head, SURMOUNT-5 did not show a dramatic difference in tolerability, but individual men often report preferring one over the other. If one drug's nausea is unmanageable even with slow titration, trying the other is a reasonable conversation to have with your prescriber. Our men's GLP-1 side-effects guide covers the day-to-day management.

Brand vs compounded: an access question, not a molecule question

Many men encounter these drugs through telehealth programs that offer compounded semaglutide or tirzepatide rather than Wegovy or Zepbound. The differences matter:

• FDA status. Wegovy and Zepbound are FDA-approved products made under FDA-reviewed manufacturing. Compounded versions are prepared by pharmacies and are not FDA-approved; the FDA does not review them for safety, effectiveness or quality before they reach you.
• Regulatory flux. Compounding of these molecules has been under active FDA scrutiny since the national shortages ended. In 2026 the FDA proposed excluding semaglutide and tirzepatide from the list of bulk substances that large outsourcing facilities may use. Ask any provider where your medication is compounded and how they're handling the rules as they stand today.
• Dosing conventions. Compounded products may come in vials with doses drawn by syringe rather than prefilled pens, which puts more responsibility on you to measure correctly.

Whichever route you choose, the clinical comparison above still applies: the molecule determines the expected effect; the source determines the regulatory protections around it.

How men usually end up choosing

In real life, the choice is rarely made on trial data alone. These are the questions that typically decide it:

1. Coverage. If your insurer covers one and not the other, that often settles it.
2. Diabetes or other conditions. Men with type 2 diabetes, heart disease, sleep apnea or kidney disease may have indication-specific reasons to favor one product. Semaglutide (Wegovy) carries a cardiovascular risk-reduction indication; Zepbound has an obstructive sleep apnea indication.
3. Weight-loss goal. If you need a larger reduction, the SURMOUNT-5 averages favor tirzepatide.
4. Tolerability history. A man who did poorly on one is often switched to the other.
5. Supply and convenience. Pen vs vial, pharmacy availability, and refill reliability matter over a treatment that may last years.

Getting evaluated

A legitimate program will take a full medical history (including thyroid cancer history, pancreatitis, gallbladder disease and current medications), confirm you meet the BMI criteria, and explain which molecule and source they're prescribing and why. If you want to compare program options, our weight-loss hub lists the providers we cover.